정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 982 | Active, not recruiting | Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED | COVID19 | Drug: Nitric Oxide Gas Other: Inhaled Supplemental Oxygen |
Phase 2 | Massachusetts General Hospital, Department of Anesthesia, MGH | OTHER | 47 | All | 18 Years | Massachusetts General Hospital, Boston, Massachusetts, United States |
| 981 | Not yet recruiting | Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection | SARS-CoV-2 Infection | Drug: Nitric Oxide Device: Nasal spray with isotonic saline |
Phase 3 | Sanotize Research and Development corp. | INDUSTRY | 13000 | All | 18 Years | |
| 980 | Withdrawn | Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection | SARS-CoV Infection | Drug: Nitric Oxide-Releasing Drug | Phase 2 | Sanotize Research and Development corp. | INDUSTRY | 0 | All | 18 Years | |
| 979 | Completed | Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection | Corona Virus Infection | Drug: NORS (Nitric Oxide Releasing Solution) Drug: NORS (Nitric Oxide Releasing Solution) |
Phase 2 | Sanotize Research and Development corp., The Emmes Company, LLC, Keyrus Life Science | INDUSTRY | 143 | All | 19 Years | BC Diabetes, Vancouver, British Columbia, Canada LMC Manna, Pointe-Claire, Quebec, Canada Diex Recherche Quebec, Quebec, Quebec, Canada Diex Recherche Joliette, Saint-Charles-Borromee, Quebec, Canada Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada |
| 978 | Active, not recruiting | Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement | Coronavirus Infection | Drug: Nitric Oxide-Sessions Drug: Nitric Oxide-Continuous and Sessions |
Phase 2 | Tomsk National Research Medical Center of the Russian Academy of Sciences, Siberian State Medical University | OTHER | 20 | All | 18 Years | Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation |
| 977 | Recruiting | NK Cells Treatment for COVID-19 | Novel Coronavirus Pneumonia | Biological: NK Cells | Phase 1 | Xinxiang medical university, First Affiliated Hospital of Xinjiang Medical University | OTHER | 30 | All | 18 Years ~ 65 Years | The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China |
| 976 | Active, not recruiting | NO Prevention of COVID-19 for Healthcare Providers | Healthcare Associated Infection | Drug: Inhaled nitric oxide gas | Phase 2 | Massachusetts General Hospital | OTHER | 24 | All | 18 Years ~ 99 Years | Massachusetts General Hospital, Boston, Massachusetts, United States |